pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
pharmadog news

Browse

2,892 stories matching this filter · ← front page

★ save view↓export CSV
rangeto
sort
recentoldestsourcealpha
source
STAT1212Endpoints918BioPharma Dive354BioSpace335Fierce Biotech314onclive165raps111globenewswire health
therapy area
allOncology8102Rare Disease1929Cardiology1871Immunology1544Hematology1353Vaccines1253Pulmonology
  • Opinion: Trump administration’s paperwork surge hampers science and health care
    The opinion piece argues that the Trump administration has expanded paperwork requirements, making it harder for scientists and Medicaid recipients to access services. Citing a federal estimate th…
    STAT · 11d agoNegative↗ source
  • ARCH Venture Partners aims to raise $3 billion for its 14th biotech fund
    ARCH Venture Partners, a leading biotech venture capital firm, announced its intention to raise about $3 billion for a new fund. The proposed fund would be the firm's 14th and would rank among the…
    Endpoints · 11d agoDealNeutral↗ source
← prev
page 12 of 116
next →
73
fda recalls71
fda medwatch62
fda press38
1252
Psychiatry & CNS882
Ophthalmology520
Pain501
Endocrinology & Metabolism493
Infectious Disease456
  • Alumis' TYK2 lupus drug fails mid-stage trial, CEO says clear path forward
    Alumis announced that its TYK2 inhibitor did not meet primary endpoints in a mid-stage study in patients with lupus. The trial, which was the company's lead program, was designed to evaluate effic…
    Endpoints · 10d agoNegative readoutNegative↗ source
  • House passes stopgap bill to block White House plan for political control of federal research grants
    The House approved a temporary funding measure that blocks a White House proposal to let political appointees oversee federal research grants. The measure passed 370‑48 and mirrors a Senate bill p…
    STAT · 10d agoRegulatoryNeutral↗ source
  • K Health plans IPO by 2029 after recent funding round
    K Health, a virtual‑care company that uses AI, announced its intention to go public by 2029. CEO Allon Bloch made the comment after a recent fundraising round, signalling the firm is preparing for…
    Endpoints · 10d agoPositive↗ source
  • Arsenal Biosciences cuts 99 jobs as it pivots to in vivo CAR-T therapy
    Arsenal Biosciences announced another round of layoffs, eliminating 99 positions, which represents the majority of its workforce after a prior 50% reduction last year. The cuts are part of a strat…
    BioSpace · 10d agoLayoffsNegative↗ source
  • Trump announces voluntary pricing agreements with nine new drug makers
    President Donald Trump hosted a drug pricing event on Monday, joined by executives from several pharmaceutical companies and senior health officials. At the meeting he announced voluntary pricing…
    Endpoints · 10d agoRegulatoryNeutral↗ source
  • Arsenal Biosciences trims most of its workforce as it shifts focus to in vivo CAR T therapy
    Arsenal Biosciences announced another round of staff reductions, letting go of the majority of its employees. This follows a previous reduction about a year ago that cut roughly half of its workfo…
    Endpoints · 10d agoLayoffsNegative↗ source
  • Mid-size biotechs join White House Medicaid pricing program, gain tariff relief
    Nine mid-size drugmakers announced they will take part in the White House’s GENEROUS Medicaid pricing model, which ties U.S. Medicaid payments to the lowest prices paid abroad. In return, the comp…
    BioPharma Dive · 10d agoRegulatoryNeutral↗ source
  • NIH proposes cap on individual research grants, drawing mixed reactions
    The National Institutes of Health has floated a plan to limit the number of active research grants any single scientist can hold. The proposal is part of the agency’s effort to balance its research…
    STAT · 11d agoRegulatoryNeutral↗ source
  • ADA internal review rejects claims of silencing protest after member expulsions
    An internal review by the American Diabetes Association examined the removal of five participants from its scientific sessions in New Orleans. The expulsions occurred after the individuals distribu…
    STAT · 10d agoNeutral↗ source
  • ADA reviews June conference disruptions, finds no censorship of editorial
    American Diabetes Association CEO Charles "Chuck" Henderson apologized after several attendees were removed from the June 5 Scientific Sessions in New Orleans for repeated disruptions. He said the…
    STAT · 10d agoNeutral↗ source
  • Google Gemini adds Zocdoc booking, while Solv partners with Amazon
    In August, Google revealed that users of its Gemini AI platform can schedule medical appointments directly through Zocdoc, integrating AI assistance with healthcare scheduling. The move expands Ge…
    Endpoints · 10d agoDealPositive↗ source
  • Trial over Lindsay Clancy’s case threatens progress in postpartum psychiatry
    Opinion piece by reproductive psychiatrist Jennifer Okwerekwu notes that the ongoing Lindsay Clancy trial, in which a jury remains deadlocked after five weeks, pits a defense claim of health-care s…
    STAT · 10d agoNegative↗ source
  • Dietitian Shortage Threatens Trump Administration's Nutrition Initiatives
    The Trump administration's Make America Healthy Again (MAHA) plan has shifted nutrition guidance, promoting more protein, cutting processed foods, and revamping meals in schools, military bases and…
    STAT · 11d agoNegative↗ source
  • FDA clears Takeda and Protagonist's rusfertide (Mimrylo) for polycythemia vera, opening potential $2 billion market
    The Food and Drug Administration has granted clearance to rusfertide, sold under the brand name Mimrylo, for the treatment of polycythemia vera, a rare blood disorder that causes excess red blood c…
    BioPharma Dive · 11d agoApprovalPositive↗ source
  • Biomarin nabs big royalties in achondroplasia patent settlement with Ascendis
    Biomarin has granted Ascendis a non-exclusive, worldwide license to use navepegritide, the active ingredient in the latter company’s recently approved achondroplasia drug Yuviwel, in exchange for 1…
    BioSpace · 11d agoApprovalPositive↗ source
  • Takeda and Protagonist Therapeutics receive FDA approval for rusfertide (Mimrylo) to treat polycythemia vera
    The FDA approved rusfertide, to be sold as Mimrylo, for the treatment of polycythemia vera, a rare blood cancer, marking a key win for Takeda and its partner Protagonist Therapeutics. The decision…
    BioSpace · 11d agoApprovalPositive↗ source
  • Eli Lilly to acquire Merida Biosciences in near-$2.9 billion deal to expand immune-disease pipeline
    Eli Lilly announced it will buy privately held Merida Biosciences, a company that has created a technology to target and break down malfunctioning antibodies that drive many autoimmune disorders.…
    BioPharma Dive · 11d agoDealPositive↗ source
  • Eli Lilly to acquire Merida Biosciences for up to $2.875 billion, bolstering its immunology pipeline
    Eli Lilly announced a deal to purchase Merida Biosciences, a biotech focused on immunology, for a total consideration that could reach $2.875 billion. The acquisition adds Merida's assets in fast-…
    Endpoints · 11d agoDealPositive↗ source
  • US biotech edge erodes as China overtakes in trials and research, raising security concerns
    The United States is losing its lead in biotech as China now conducts more clinical trials and publishes more natural‑science papers. China passed the U.S. six years ago in trial numbers and soon…
    BioSpace · 12d agoNegative↗ source
  • Cytokinetics reports Phase 3 success for Myqorzo but shares tumble as investors weigh market impact
    At the European Society of Cardiology meeting, Cytokinetics presented Phase 3 data for Myqorzo in non‑obstructive hypertrophic cardiomyopathy, showing benefit in both forms of the disease and disti…
    BioPharma Dive · 11d agoPositive readoutNeutral↗ source
  • Eli Lilly to acquire Merida Biosciences in up to $2.9 billion deal for precision antibody-degrading therapies
    Eli Lilly announced it will purchase Massachusetts‑based Merida Biosciences, adding a platform that can selectively degrade disease‑causing antibodies. The transaction could total up to $2.875 bil…
    BioSpace · 11d agoDealPositive↗ source
  • FDA approves Takeda/Protagonist cancer drug Mimrylo as White House readies new drug pricing deals, BioNTech ends colon vaccine trial
    The U.S. Food and Drug Administration gave approval to a weekly injection called Mimrylo, developed by Takeda and partner Protagonist Therapeutics, for treatment of a slow‑growing cancer. The agenc…
    STAT · 11d agoApprovalNeutral↗ source
  • Novartis and Bristol Myers pause autoimmune CAR-T trials after safety concerns
    Novartis announced a temporary hold on its personalized CAR-T therapy rap-cel after three patients experienced immune effector cell-associated hemophagocytic syndrome, a rare and potentially life-t…
    BioPharma Dive · 11d agoRegulatoryNegative↗ source